These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 8841502

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P, Riantawan P, Lebnak P, Getngern P.
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [Abstract] [Full Text] [Related]

  • 3. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F, Aydiner A, Topuz E, Yasasever V, Karadeniz A, Saip P.
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [Abstract] [Full Text] [Related]

  • 4. [Clinical usefulness of serum assay of EIA-CYFRA 21-1 in lung cancer].
    Satoh H, Yagyu H, Sumi M, Ishikawa H, Hamada M, Suyama T, Naitoh T, Inoue M, Saitoh T, Uchida Y.
    Gan To Kagaku Ryoho; 1994 May; 21(6):795-9. PubMed ID: 7514388
    [Abstract] [Full Text] [Related]

  • 5. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H, Eguchi K, Shinkai T, Tamura T, Ohe Y, Oshita F, Saijo N, Kondo H, Oki K, Okura H.
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W, Hoppe M, Muley T, Drings P.
    Anticancer Res; 1997 Oct; 17(4B):2875-8. PubMed ID: 9329552
    [Abstract] [Full Text] [Related]

  • 10. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R, Auge JM, Filella X, Viñolas N, Alicarte J, Domingo JM, Ballesta AM.
    Anticancer Res; 2005 Oct; 25(3A):1773-8. PubMed ID: 16033098
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
    Pastor A, Menéndez R, Cremades MJ, Pastor V, Llopis R, Aznar J.
    Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S, Kimura H, Iwai N, Shima M, Ando M, Kuriyama T.
    Anticancer Res; 2001 Mar; 21(4B):3085-92. PubMed ID: 11712815
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
    Kulpa J, Wójcik E, Radkowski A, Kolodziejski L, Stasik Z.
    Anticancer Res; 2000 Mar; 20(6D):5035-40. PubMed ID: 11326663
    [Abstract] [Full Text] [Related]

  • 18. [The importance of the tumor marker CYFRA 21-1 in patients with lung cancer after surgery or chemotherapy].
    Zissimopoulos A, Stellos K, Permenopoulou V, Petrakis G, Theodorakopoulos P, Baziotis N, Thalassinos N.
    Hell J Nucl Med; 2007 Mar; 10(1):62-6. PubMed ID: 17450257
    [Abstract] [Full Text] [Related]

  • 19. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM, Sauer-Eppel H, Bruzdziak TH.
    Anticancer Res; 2007 Mar; 27(4A):1911-5. PubMed ID: 17649794
    [Abstract] [Full Text] [Related]

  • 20. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
    Pan QR, Zhang X, Xu ZF, Zheng S.
    Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.